MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 574879 | Name: Soraprazan
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Soraprazan is a reversible and fast-acting inhibitor of gastric H,K-ATPase.

Chemical Structure

Soraprazan
Soraprazan
CAS#261944-46-1

Theoretical Analysis

MedKoo Cat#: 574879

Name: Soraprazan

CAS#: 261944-46-1

Chemical Formula: C21H25N3O3

Exact Mass: 367.1896

Molecular Weight: 367.45

Elemental Analysis: C, 68.64; H, 6.86; N, 11.44; O, 13.06

Price and Availability

Size Price Availability Quantity
2mg USD 305.00 2 Weeks
5mg USD 600.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Soraprazan
IUPAC/Chemical Name
(7R,8R,9R)-8-Hydroxy-2,3-dimethyl-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine
InChi Key
PWILYDZRJORZDR-MISYRCLQSA-N
InChi Code
InChI=1S/C21H25N3O3/c1-13-14(2)24-10-9-16-18(21(24)22-13)23-17(15-7-5-4-6-8-15)19(25)20(16)27-12-11-26-3/h4-10,17,19-20,23,25H,11-12H2,1-3H3/t17-,19-,20-/m1/s1
SMILES Code
COCCO[C@H]1[C@H](O)[C@@H](C2=CC=CC=C2)NC3=C1C=CN4C3=NC(C)=C4C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 367.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kanu JE, Soldera J. Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis. World J Gastroenterol. 2024 Mar 7;30(9):1213-1223. doi: 10.3748/wjg.v30.i9.1213. PMID: 38577188; PMCID: PMC10989498. 2: Kamboj P, Tyagi V. Enzymatic Synthesis of Indole-Based Imidazopyridine using α-Amylase. Chembiochem. 2024 Mar 15;25(6):e202300824. doi: 10.1002/cbic.202300824. Epub 2024 Feb 20. PMID: 38279707. 3: Dhooge PPA, Möller PT, Boon CJF, Lotery AJ, Herrmann P, Battaglia Parodi M, Klein W, Fsadni MG, Wheeler-Schilling TH, Jungmann O, Müller H, Holz FG, Schmitz-Valckenberg S, Peters TM, Stingl K, Hoyng CB; Soraprazan Consortium. The STArgardt Remofuscin Treatment Trial (STARTT): design and baseline characteristics of enrolled Stargardt patients. Open Res Eur. 2022 Sep 27;1:96. doi: 10.12688/openreseurope.13872.3. PMID: 37645124; PMCID: PMC10445898. 4: Dhooge PPA, Möller PT, Meland N, Stingl K, Boon CJF, Lotery AJ, Parodi MB, Herrmann P, Klein W, Fsadni MG, Wheeler-Schilling TH, Holz FG, Hoyng CB, Schmitz-Valckenberg S; Soraprazan Consortium. Repeatability of Quantitative Autofluorescence Imaging in a Multicenter Study Involving Patients With Recessive Stargardt Disease 1. Transl Vis Sci Technol. 2023 Feb 1;12(2):1. doi: 10.1167/tvst.12.2.1. PMID: 36723966; PMCID: PMC9904328. 5: Tanaka S, Morita M, Yamagishi T, Madapally HV, Hayashida K, Khandelia H, Gerle C, Shigematsu H, Oshima A, Abe K. Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump. J Med Chem. 2022 Jun 9;65(11):7843-7853. doi: 10.1021/acs.jmedchem.2c00338. Epub 2022 May 23. PMID: 35604136. 6: Oh M, Yeom J, Schraermeyer U, Julien-Schraermeyer S, Lim YH. Remofuscin induces xenobiotic detoxification via a lysosome-to-nucleus signaling pathway to extend the Caenorhabditis elegans lifespan. Sci Rep. 2022 May 3;12(1):7161. doi: 10.1038/s41598-022-11325-2. PMID: 35504961; PMCID: PMC9064964. 7: Stingl K, Hoyng C, Kempf M, Kohl S, Jung R, Righetti G, Kühlewein L, Pohl L, Kortüm F, Kelbsch C, Wilhelm B, Peters T, Stingl K; SORAPRAZAN consortium. Evaluation of Local Rod and Cone Function in Stargardt Disease. Invest Ophthalmol Vis Sci. 2022 Mar 2;63(3):6. doi: 10.1167/iovs.63.3.6. PMID: 35262734; PMCID: PMC8934563. 8: Fang Y, Taubitz T, Tschulakow AV, Heiduschka P, Szewczyk G, Burnet M, Peters T, Biesemeier A, Sarna T, Schraermeyer U, Julien-Schraermeyer S. Removal of RPE lipofuscin results in rescue from retinal degeneration in a mouse model of advanced Stargardt disease: Role of reactive oxygen species. Free Radic Biol Med. 2022 Mar;182:132-149. doi: 10.1016/j.freeradbiomed.2022.02.025. Epub 2022 Feb 25. PMID: 35219849. 9: Julien-Schraermeyer S, Illing B, Tschulakow A, Taubitz T, Guezguez J, Burnet M, Schraermeyer U. Penetration, distribution, and elimination of remofuscin/soraprazan in Stargardt mouse eyes following a single intravitreal injection using pharmacokinetics and transmission electron microscopic autoradiography: Implication for the local treatment of Stargardt's disease and dry age-related macular degeneration. Pharmacol Res Perspect. 2020 Dec;8(6):e00683. doi: 10.1002/prp2.683. PMID: 33164337; PMCID: PMC7649431. 10: Devi N, Singh D, Rawal RK, Bariwal J, Singh V. Medicinal Attributes of Imidazo[1,2-a]pyridine Derivatives: An Update. Curr Top Med Chem. 2016;16(26):2963-2994. doi: 10.2174/1568026616666160506145539. PMID: 27150367. 11: Julien S, Schraermeyer U. Lipofuscin can be eliminated from the retinal pigment epithelium of monkeys. Neurobiol Aging. 2012 Oct;33(10):2390-7. doi: 10.1016/j.neurobiolaging.2011.12.009. Epub 2012 Jan 12. PMID: 22244091. 12: Simon WA, Herrmann M, Klein T, Shin JM, Huber R, Senn-Bilfinger J, Postius S. Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007 Jun;321(3):866-74. doi: 10.1124/jpet.107.120428. Epub 2007 Mar 16. PMID: 17369284. 13: Shin JM, Grundler G, Senn-Bilfinger J, Simon WA, Sachs G. Functional consequences of the oligomeric form of the membrane-bound gastric H,K-ATPase. Biochemistry. 2005 Dec 13;44(49):16321-32. doi: 10.1021/bi051342q. PMID: 16331993.